American Heart Journal
Volume 157, Issue 1 , Pages 22-29 , January 2009

Prognostic impact of Chagas disease in the United States

Received 25 April 2008 ,Accepted 25 August 2008.

References 

  1. Levy MZ, Bowman NM, Kawai V, et al. Periurban Trypanosoma cruzi infected triatoma infestans, arequipa, Peru. Emerg Infect Dis. 2006;12:1345–1352
  2. Milei J, Mautner B, Storino RA, et al. Does Chagas' disease exist as an undiagnosed form of cardiomyopathy in the United States?. Am Heart J. 1992;123:1732–1735
  3. Milei J, Fernandez Alonso G, Vanzulli S, et al. Myocardial Inflammatory infiltrate in human chronic chagasic cardiomyopathy: immunohistochemical findings. Cardiovasc Pathol. 1996;5:209–219
  4. Storino RA, Milei J. Enfermedad de Chagas. Buenos Aires: Mosby-Doyma; 1994;
  5. Milei J, Guerri-Guttenberg RA, Azzato F, et al. Chagasic cardiomyopathy: mew trends for an old burden. Cardiomyopathies: causes, effects and treatment. Hauppauge (NY): Nova Science Publishers; 2008;(in press)
  6. Milei J, Pesce R, Valero E, et al. Electrophysiologic-structural correlations in chagasic aneurysms causing malignant arrhythmias. Int J Cardiol. 1991;32:65–74
  7. Gascón J, Albajar P, Cañas E, et al. Diagnosis, management, and treatment of chronic Chagas' heart disease in areas where Trypanosoma cruzi infection is not endemic. Rev Esp Cardiol. 2007;60:285–293
  8. Center for Disease Control and Prevention. Division of Parasitic Diseases (DPD) . Antiparasitic treatment of Chagas disease. Available at http://www.cdc.gov/chagas/hcp/tx.html2007;Last accessed July 2, 2008
  9. Ferrans VJ, Milei J, Tomita Y, et al. Basement membrane thickening in cardiac myocytes and capillaries in chronic Chagas' disease. Am J Cardiol. 1988;61:1137–1140
  10. Storino RA, Milei J, Beigelman R, et al. Enfermedad de Chagas: doce años de seguimiento en área urbana. Rev Argent Cardiol. 1992;60:205–216
  11. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States. JAMA. 2007;298:2171–2181
  12. Cançado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med trop S Paulo. 2002;44:29–37
  13. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. Ann Intern Med. 2006;144:724–734
  14. Lauria Pires L, Braga MS, Vexenat AC, et al. Progressive chronic Chagas heart disease ten years after treatment with anti–trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg. 2000;63:111–118
  15. de Andrade AL, Zicker F, Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996;348:1407–1413
  16. Solari A, Ortiz S, Soto A, et al. Treatment of Trypanosoma cruzi–infected children with nifurtimox: a 3 year follow up by PCR. J Antimicrob Chemother. 2001;48:515–519
  17. Garcia S, Ramos CO, Senra JFV, et al. Treatment with benznidazole during the chronic phase of experimental Chagas disease decreases cardiac alterations. Antimicrob Agents Chemother. 2005;9:1521–1528
  18. Fabbro DL, Streiger ML, Arias ED, et al. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe City (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evaluation. Rev Soc Bras Med Trop. 2007;40:1–10
  19. Bocchi EA, Bellotti G, Mocelin AO, et al. Heart transplantation for chronic Chagas' heart disease. Ann Thorac Surg. 1996;61:1727–1733
  20. Benvenuti LA, Roggério A, Sambiase NV, et al. Polymerase chain reaction in endomyocardial biopsies for monitoring reactivation of Chagas' disease in heart transplantation. A case report and review of the literature. Cardiovasc Pathol. 2005;14:265–268
  21. Borda ES, Sterin-Borda L. Antiadrenergic and mucarinic receptor antibodies in Chagas' cardiomyopathy. Int J Cardiol. 1996;54:149–156
  22. Black CL, Ocaña S, Riner D, et al. Household risk factors for trypanosoma cruzi seropositivity in two geographic regions of ecuador. J Parasitol. 2007;93:12–16
  23. Anonymous . Latin America's plague. Darwin's disease. The Economist May 5. 1990;
  24. Hancock K, Zajac AM, Pung OJ, et al. Prevalence of antibodies to Trypanosoma cruzi in raccoons (Procyon lotor) from an urban area of northern Virginia. J Parasitol. 2005;91:470–472
  25. Dorn PL, Perniciaro L, Yabsley MJ, et al. Autochthonous transmission of Trypanosoma cruzi, Louisiana. Emerg Infect Disease. 2007;13:605–607
  26. Hall CA, Polizzi C, Yabsley MJ, et al. Trypanosoma cruzi prevalence and epidemiologic trends in lemurs on St. Catherines island, Georgia. J Parasitol. 2007;93:93–96
  27. Beard CB, Pye G, Steurer FJ, et al. Chagas Disease in a domestic transmission cycle in Southern Texas, USA. Emerg Infect Dis. 2003;9:103–105
  28. Kjos SA, Snowden KF, Craig TM, et al. Distribution and characterization of canine Chagas disease in Texas. Vet Parasitol. 2008;
  29. Hanford EJ, Zhan FB, Lu Y, et al. Chagas disease in Texas: recognizing the significance and implications of evidence in the literature. Soc Sci Med. 2007;65:60–79
  30. Wisnivesky-Colli C, Schweigmann N, Alberti A, et al. Sylvatic American trypanosomiasis in Argentina. Trypanosoma cruzi infection in mammals from the Chaco forest in Santiago del Estero. Trans R Soc Trop Med Hyg. 1992;86:38–41
  31. Schweigmann NJ, Pietrokovsky S, Bottazzi V, et al. Prevalence of trypanosoma cruzi infection in opossum (Didelphis albiventris) in Santiago del Estero, Argentina. Rev Panam Salud Publica. 1999;6:371–377
  32. Castañera MB, Lauricella MA, Chuit R, et al. Evaluation of dogs as sentinels of the transmission of Trypanosoma cruzi in a rural area of north-western Argentina. Ann Trop Med Parasitol. 1998;92:671–683
  33. Segura EL, Perez A, Yanovsky J, et al. Disminución en la prevalencia de infección por Trypanosoma cruzi (enfermedad de Chagas) en hombres jóvenes de la Argentina. Bol Of Sanit Panam. 1986;90:311
  34. Gürtler RE, Cecere MC, Lauricella MA, et al. Domestic dogs and cats as sources of Trypanosoma cruzi infection in rural northwestern Argentina. Parasitology. 2007;134:69–82
  35. Schiffler RJ, Mansur GP, Navin TR, et al. Indigenous Chagas' disease (American trypanosomiasis) in California. JAMA. 1984;251:2983–2984
  36. Woody NC, Woody HB. American trypanosomiasis (Chagas' disease): first indigenous case in the United States. JAMA. 1955;159:676–677
  37. Herwaldt BL, Grijalva MJ, Newsome AL, et al. Use of polymerase chain reaction to diagnose the fifth reported US case of autochthonous transmission of Trypanosoma cruzi, in Tennessee, 1998. J Infect Dis. 2000;181:395–399
  38. Ochs DE, Hnilica VS, Moser DR, et al. Postmortem diagnosis of autochthonous acute chagasic myocarditis by polymerase chain reaction amplification of a species-specific DNA sequence of Trypanosoma cruzi. Am J Trop Med Hyg. 1996;54:526–529
  39. Porcasi X, Hrellac H, Catalá S, et al. Infestation of rural houses by Triatoma infestans in the region of Los Llanos (La Rioja, Argentina). Mem Inst Oswaldo Cruz. 2007;102:63–68
  40. Guzman-Tapia Y, Ramirez-Sierra MJ, Escobedo-Ortegon J, et al. Effect of hurracane Isidore on triatoma dimidiata distribution and chagas disease transmission risk in the yucatán peninsula of Mexico. Am J Trop Med Hyg. 2005;73:1019–1025
  41. Garratty G, Glynn SA, McEntire R. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion. 2004;44:703–706
  42. Young C, Losikoff P, Chawla A, et al. Transfusion-acquired Trypanosoma cruzi infection. Transfusion. 2007;47:540–545
  43. Leiby DA, Herron RM, Read EJ, et al. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion. 2002;42:549–555
  44. Center for Disease Control and Prevention (CDC) . Blood donor screening for Chagas disease—United States, 2006-2007. MMWR Morb Mortal Wkly Rep. 2007;56:141–143
  45. Hernández-Becerril N, Mejía AM, Ballinas-Verdugo MA, et al. Blood transfusion and iatrogenic risk in Mexico city. Anti–trypanosoma cruzi seroprevalence in 43,048 blood donors, evaluation of parasitemia, and electrocardiogram findings in seropositive. Mem Inst Oswaldo Cruz. 2005;100:111–116
  46. Center for Disease Control and Prevention (CDC) . Chagas disease after organ transplantation—Los Angeles, California, 2006. MMWR Morb Mortal Wkly Rep. 2006;55:798–800
  47. Center for Disease Control and Prevention (CDC) . Chagas disease after organ transplantation—United States, 2001. MMWR Morb Mortal Wkly Rep. 2001;51:210–212
  48. Dedet J, Pratlong F. Leishmania, Trypanosoma and monoxenous trypanosomatids as emerging opportunistic agents. J Eukaryot Microbiol. 2000;47:37–39
  49. Cordova E, Boschi A, Ambrosioni J. Reactivation of Chagas disease with central nervous system involvement in HIV-infected patients in Argentina, 1992-2007. Int J Infect Dis. 2008;Mar 10 [electronic publication ahead of print]
  50. Nowicki MJ, Chinchilla C, Corado L, et al. Prevalence of antibodies to Trypanosoma cruzi among solid organ donors in Southern California: a population at risk. Transplantation. 2006;81:477–479
  51. Buekens P, Almendares O, Carlier Y, et al. Mother-to-child transmission of Chagas' disease in North America: why don't we do more?. Matern Child Health J. 2007;
  52. Schumnis G. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz. 2007;102:75–85

PII: S0002-8703(08)00743-6

doi: 10.1016/j.ahj.2008.08.024

American Heart Journal
Volume 157, Issue 1 , Pages 22-29 , January 2009

Article Tools

* Image Usage & Resolution